IP Library › Granted Patent US 12697314
Granted Patent B2
US 12697314 · App. 19/242,517 · Granted Aug 4, 2026

Pharmaceutical composition for treating autosomal dominant polycystic kidney disease

Inventors: Kenji Osafune (Kyoto, JP); Shinichi Mae (Kyoto, JP); Saori Nishio (Sapporo, JP); Fumihiko Hattanda (Sapporo, JP); Tsuyoshi Nakano (Kyoto, JP); Ryuichiro Hirayama (Kyoto, JP); Tomoko Suzuki (Kyoto, JP); Ayuto Hayashi (Kyoto, JP)
Assignees: KYOTO UNIVERSITY; NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
A61K31/192A61P13/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697314
App. No.
19/242,517
Granted
Aug 4, 2026
Kind
B2
Abstract

A new dosage regimen of a pharmaceutical composition comprising tamibarotene as the active ingredient for treating autosomal dominant polycystic kidney disease. A pharmaceutical composition comprising tamibarotene for the treatment or prevention of autosomal dominant polycystic kidney disease (ADPKD), wherein the composition is administered orally to a patient with ADPKD in an amount of 1.4-5.5 mg/day, particularly 4.0 mg/day of tamibarotene.

Claims (2)

1 . A method for treating autosomal dominant polycystic kidney disease (ADPKD) in a subject in need thereof, the method comprising administering 1.4-5.5 mg/day of tamibarotene orally to the subject.

2 . A method for treating autosomal dominant polycystic kidney disease (ADPKD) in a subject in need thereof, the method comprising administering about 4 mg/day of tamibarotene orally to the subject.